Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis
Diagnosis and classification of acute myeloid leukemia (AML) are based on morphology and genetics. An increasing number of gene mutations have been found, and some are used for risk classification in AML patients with normal karyotype (cytogenetically normal (CN)-AML). In this systematic review and meta-analysis, we examined three frequent mutations in CN-AML: mutations of fms-related tyrosine kinase 3 (FLT3-ITD), mutated nucleophosmin (NPM1), and mutations of the CCAAT enhancer-binding protein alpha (CEBPA) gene. A systematic literature search of publications listed in the electronic databases (Embase, Pubmed, Healthstar, BIOSIS, ISI Web of Knowledge and Cochrane) from 2000 up to March 2012 was performed (Fig. 1). Nineteen studies were included and qualitatively analyzed. Two to four studies entered the quantitative meta-analysis incorporating 1,378 to 1,942 patients with CN-AML. Meta-analysis for overall survival (OS) and relapse-free survival (RFS) showed FLT3-ITD to predict an unfavorable prognosis, with hazard ratios (HR) of 1.86 and 1.75, respectively. In contrast, meta-analysis of the impact of NPM1 and CEBPA mutations on OS yielded an HR of 0.56 for each mutation, while analysis of impact on RFS produced HRs of 0.37 and 0.42, respectively. This systematic review and meta-analysis aimed to evaluate the prognostic value of mutations in the NPM1, CEBPA, and FLT3 genes. FLT3-ITD was associated with worse prognosis, whereas mutations in NPM1 and CEBPA genes were associated with a favorable prognosis.
Acute myeloid leukemia Normal karyotype Mutations of fms-related tyrosine kinase 3 Mutated nucleophosmin Mutations of the CEBPA gene Meta-analysis
This is a preview of subscription content, log in to check access.
This work was supported by the Bundesministerium für Bildung und Forschung/Germany.
We are very thankful to Michael Morgan carefully reading the manuscript.
Conflict of interest
All authors have no conflict of interest to declare.
Grimwade D, Hills RK, Moorman AV et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354–365. doi:10.1182/blood-2009-11-254441PubMedCrossRefGoogle Scholar
Damm F, Heuser M, Morgan M et al (2010) Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol 28:578–585. doi:10.1200/JCO.2009.23.0342PubMedCrossRefGoogle Scholar
Dohner K, Schlenk RF, Habdank M et al (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106:3740–3746. doi:10.1182/blood-2005-05-2164PubMedCrossRefGoogle Scholar
Dunna NR, Rajappa S, Digumarti R et al (2010) Fms like tyrosine kinase (FLT3) and nucleophosmin 1 (NPM1) mutations in de novo normal karyotype acute myeloid leukemia (AML). Asian Pac J Cancer Prev 11:1811–1816PubMedGoogle Scholar
Fröhling S, Schlenk RF, Stolze I et al (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22:624–633. doi:10.1200/JCO.2004.06.060PubMedCrossRefGoogle Scholar
Gale RE, Green C, Allen C et al (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111:2776–2784PubMedCrossRefGoogle Scholar
Langer C, Marcucci G, Holland KB et al (2009) Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 27:3198–3204. doi:10.1200/JCO.2008.20.6110PubMedCentralPubMedCrossRefGoogle Scholar
Langer C, Radmacher MD, Ruppert AS et al (2008) High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) st. Blood 111:5371–5379. doi:10.1182/blood-2007-11-124958PubMedCentralPubMedCrossRefGoogle Scholar
Marcucci G, Maharry K, Radmacher MD et al (2008) Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol 26:5078–5087. doi:10.1200/JCO.2008.17.5554PubMedCentralPubMedCrossRefGoogle Scholar
Taskesen E, Bullinger L, Corbacioglu A, et al. (2011) Prognostic impact, concurrent genetic mutations and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 117:2469–2475. doi:10.1182/blood-2010-09-307280
Virappane P, Gale R, Hills R et al (2008) Mutation of the Wilms’ tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 26:5429–5435. doi:10.1200/JCO.2008.16.0333PubMedCrossRefGoogle Scholar
Wagner K, Damm F, Goehring G et al (2010) Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 28:2356–2364. doi:10.1200/JCO.2009.27.6899PubMedCrossRefGoogle Scholar
Whitman SP, Ruppert AS, Radmacher MD et al (2008) FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 111:1552–1559. doi:10.1182/blood-2007-08-107946PubMedCentralPubMedCrossRefGoogle Scholar
Arber DA, Brunning RD, Le Beau MM et al (2008) Acute myeloid leukaemia and related precursor neoplasms. In: Swerdlow SH, Campo E, Harris NL (eds) WHO Classif. Tumours Haematop. Lymphoid Tissues, 4th edn. IARC Press, Lyon, pp 109–166Google Scholar
Yanada M, Matsuo K, Suzuki T et al (2005) Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leuk Off J Leuk Soc Am Leuk Res Fund UK 19:1345–1349. doi:10.1038/sj.leu.2403838CrossRefGoogle Scholar
Schlenk RF, Taskesen E, van Norden Y et al (2013) The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood 122:1576–1582. doi:10.1182/blood-2013-05-503847PubMedCrossRefGoogle Scholar